Actively Recruiting
Study of Nicotinamide Riboside to Slow Disability in Adults with Progressive Multiple Sclerosis
Led by Haukeland University Hospital · Updated on 2024-01-11
300
Participants Needed
1
Research Sites
21 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and efficacy of Nicotinamide Riboside NR for treating patients with progressive multiple sclerosis MS. The main goal is to determine whether NR can delay disability progression in people with this condition. This randomized controlled trial is designed as a phase 2 study to provide detailed insights into the effects of NR compared to placebo over an extended period. Participants who qualify will be randomly assigned to receive either 1000 mg of Nicotinamide Riboside daily or a placebo for 30 months. The study uses a double-blinded design, meaning neither the patients nor the investigators know who receives NR or placebo. The trial includes a screening period to confirm eligibility before starting treatment, and participants continue their usual disease-modifying therapies if applicable. During the study, participants will undergo regular assessments including disability progression measurement, walking tests, hand function tests, and MRI brain scans to monitor lesions and brain atrophy. The primary outcome is the proportion of patients with sustained disability progression over the 30-month treatment period. Safety and efficacy are closely monitored throughout, with detailed evaluations at baseline and follow-up visits. The total study duration per participant is 30 months, ensuring thorough observation of treatment effects.
CONDITIONS
Brief Title
Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis
Research Team
K
Kjell-Morten Myhr
Ø
Øivind Torkildsen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here